IN2014CN04809A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04809A
IN2014CN04809A IN4809CHN2014A IN2014CN04809A IN 2014CN04809 A IN2014CN04809 A IN 2014CN04809A IN 4809CHN2014 A IN4809CHN2014 A IN 4809CHN2014A IN 2014CN04809 A IN2014CN04809 A IN 2014CN04809A
Authority
IN
India
Prior art keywords
tbut
prolongs
treatment
disclosed
dry eye
Prior art date
Application number
Other languages
English (en)
Inventor
Joseph G Vehige
Peter A Simmons
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47459152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014CN04809(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of IN2014CN04809A publication Critical patent/IN2014CN04809A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/717Celluloses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN4809CHN2014 2011-12-07 2012-12-07 IN2014CN04809A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161568089P 2011-12-07 2011-12-07
US201261625401P 2012-04-17 2012-04-17
PCT/US2012/068615 WO2013086449A1 (fr) 2011-12-07 2012-12-07 Utilisation d'un système d'émulsion sensible au sel pour administrer avec efficacité des lipides dans le film lacrymal chez l'humain

Publications (1)

Publication Number Publication Date
IN2014CN04809A true IN2014CN04809A (fr) 2015-09-18

Family

ID=47459152

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4809CHN2014 IN2014CN04809A (fr) 2011-12-07 2012-12-07

Country Status (28)

Country Link
US (2) US20130150324A1 (fr)
EP (5) EP3666257A1 (fr)
JP (1) JP6142419B2 (fr)
KR (1) KR102017922B1 (fr)
CN (2) CN104114152A (fr)
AR (1) AR089123A1 (fr)
AU (2) AU2012347459A1 (fr)
BR (1) BR112014013820A8 (fr)
CA (1) CA2858574C (fr)
CL (1) CL2014001518A1 (fr)
CO (1) CO6990739A2 (fr)
DK (2) DK2787969T3 (fr)
ES (2) ES2896336T3 (fr)
HK (2) HK1201458A1 (fr)
HU (2) HUE049489T2 (fr)
IL (1) IL233008A (fr)
IN (1) IN2014CN04809A (fr)
MX (1) MX355216B (fr)
MY (1) MY173378A (fr)
PH (1) PH12014501296A1 (fr)
PL (2) PL2787969T3 (fr)
PT (2) PT2787968T (fr)
RU (1) RU2014127074A (fr)
SG (1) SG11201403013VA (fr)
SI (2) SI2787969T1 (fr)
TW (1) TWI652072B (fr)
WO (2) WO2013086449A1 (fr)
ZA (1) ZA201404228B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
PL3266446T3 (pl) 2016-07-07 2019-05-31 Salvat Lab Sa Kompozycja oftalmiczna zawierająca olej rycynowy i trójgliceryd o średniej długości łańcucha
WO2018035469A1 (fr) 2016-08-19 2018-02-22 Akrivista, LLC Méthodes de diagnostic et de traitement du syndrome de l'oeil sec et compositions de traitement d'un oeil humain
CN111295169A (zh) 2017-08-18 2020-06-16 阿克里维斯塔有限责任公司 诊断和治疗干眼综合症的方法和用于治疗人类眼睛的组合物
JP7490570B2 (ja) 2018-04-27 2024-05-27 アラーガン、インコーポレイテッド 抗微生物有効性の増強及び毒性の減少を有する亜塩素酸ナトリウム組成物

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201706A (en) 1978-09-22 1980-05-06 Burton, Parsons & Company, Inc. Treatment of corneal edema
EP0028110B1 (fr) * 1979-10-26 1984-03-07 Smith and Nephew Associated Companies p.l.c. Emulsions susceptibles d'être stérilisées en autoclave
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
IT1224795B (it) 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento
JPH0723302B1 (fr) 1989-08-03 1995-03-15
US5681555A (en) 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
DE4229494A1 (de) 1992-09-04 1994-03-10 Basotherm Gmbh Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
KR970705985A (ko) 1994-09-14 1997-11-03 우에하라 아끼라 각막 장해 복구용 점안제(Eye Drops for Repairing Corneal Disturbance)
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
FI106923B (fi) 1997-01-03 2001-05-15 Cultor Ltd Finnsugar Bioproduc Trimetyyliglysiinin käyttö kehon limakalvojen hygieniaan ja hoitoon tarkoitetuissa valmisteissa
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
IT1302307B1 (it) 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
US6585987B1 (en) 1998-11-13 2003-07-01 Continental Projects Limited Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions
JP2000159659A (ja) 1998-11-30 2000-06-13 Kazuo Tsubota 眼科用人工涙液
US6228392B1 (en) 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
RU2291685C2 (ru) 2000-07-14 2007-01-20 Аллерган Инк. Композиции, содержащие терапевтически активные компоненты, обладающие повышенной растворимостью
CA2355814C (fr) 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Composition pharmaceutique pour utilisation ophthalmologique
AU2002227206B2 (en) 2000-11-08 2006-09-21 Fxs Ventures, Llc Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
WO2004028536A1 (fr) 2002-09-30 2004-04-08 Babizhayev Mark A Methode de traitement topique de maladies de l'oeil, composition et dispositif conçus pour ce traitement
AU2003301263A1 (en) * 2002-10-18 2004-05-04 Joel S. Echols Three layer tear formulation
US20040137079A1 (en) 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
US6635654B1 (en) * 2003-01-09 2003-10-21 Allergan, Inc. Ophthalmic compositions containing loratadine
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
WO2004084877A1 (fr) 2003-03-26 2004-10-07 Menicon Co., Ltd. Composition a usage ophtalmique
CA2839930C (fr) * 2003-06-13 2016-07-05 Alcon, Inc. Compositions ophtalmologiques contenant une association synergique de d ux polymeres
TWI336257B (en) * 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
CN1878571B (zh) * 2003-11-10 2010-09-08 东丽株式会社 含有多糖类的组合物及泪液层稳定化滴眼剂
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
WO2008035246A2 (fr) * 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions contenant des composés ammonium quaternaire
CN101896160A (zh) * 2006-10-17 2010-11-24 阿勒根公司 环胞菌素组合物
CN101668511A (zh) * 2007-02-28 2010-03-10 阿西克斯医疗公司 正常化睑板腺分泌的方法和化合物
JP4929245B2 (ja) 2008-07-31 2012-05-09 株式会社ベッセル工業 工具類のグリップ
MX2011013007A (es) * 2009-06-05 2012-02-28 Allergan Inc Lagrimas artificiales y usos terapeuticos.
WO2013049621A1 (fr) * 2011-09-29 2013-04-04 The Board Of Regents Of The University Of Oklahoma Compositions ophtalmologiques comprenant des agonistes du récepteur ppar-alpha et leurs méthodes de production
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye

Also Published As

Publication number Publication date
PT2787968T (pt) 2020-06-16
EP2787969A1 (fr) 2014-10-15
US20130150324A1 (en) 2013-06-13
MY173378A (en) 2020-01-21
EP2787969B1 (fr) 2021-09-29
EP3666257A1 (fr) 2020-06-17
AU2017265181A1 (en) 2017-12-14
MX355216B (es) 2018-04-10
TW201325633A (zh) 2013-07-01
JP2015504860A (ja) 2015-02-16
HK1203057A1 (en) 2015-10-16
KR20140107383A (ko) 2014-09-04
CO6990739A2 (es) 2014-07-10
PL2787968T3 (pl) 2020-08-24
SI2787969T1 (sl) 2021-12-31
CA2858574A1 (fr) 2013-06-13
EP3981387A1 (fr) 2022-04-13
CL2014001518A1 (es) 2014-10-24
RU2018119362A (ru) 2018-11-08
ZA201404228B (en) 2015-12-23
EP2787968A1 (fr) 2014-10-15
ES2797650T3 (es) 2020-12-03
BR112014013820A2 (pt) 2017-06-13
CA2858574C (fr) 2017-05-30
WO2013086449A1 (fr) 2013-06-13
RU2018119362A3 (fr) 2021-09-07
AR089123A1 (es) 2014-07-30
AU2017265181B2 (en) 2019-06-20
IL233008A0 (en) 2014-07-31
HUE049489T2 (hu) 2020-09-28
ES2896336T3 (es) 2022-02-24
SI2787968T1 (sl) 2020-08-31
EP4403220A3 (fr) 2024-10-23
EP2787968B1 (fr) 2020-03-04
CN108969482A (zh) 2018-12-11
PH12014501296A1 (en) 2014-10-08
BR112014013820A8 (pt) 2017-06-13
SG11201403013VA (en) 2014-07-30
JP6142419B2 (ja) 2017-06-07
HK1201458A1 (en) 2015-09-04
DK2787968T3 (da) 2020-06-02
PL2787969T3 (pl) 2021-12-20
US20130197083A1 (en) 2013-08-01
EP4403220A2 (fr) 2024-07-24
DK2787969T3 (da) 2021-11-01
KR102017922B1 (ko) 2019-09-03
IL233008A (en) 2017-07-31
HUE057140T2 (hu) 2022-04-28
AU2012347459A1 (en) 2014-07-03
MX2014006804A (es) 2014-09-22
WO2013086438A1 (fr) 2013-06-13
RU2014127074A (ru) 2016-02-10
TWI652072B (zh) 2019-03-01
US9314528B2 (en) 2016-04-19
CN104114152A (zh) 2014-10-22
PT2787969T (pt) 2021-11-09

Similar Documents

Publication Publication Date Title
MY171920A (en) Prevention and treatment of ocular conditions
HK1222116A1 (zh) 用於治療青光眼的能夠植入患者的眼睛內的改善的排液閥
PH12019501902A1 (en) Ocular formulations for drug-delivery to the posterior segment of the eye
HRP20130830T1 (en) A water-in-oil type emulsion for treating a disease of the eye
MX2015001250A (es) Composiciones y tratamiento para enfermedades y trastornos del ojo.
IN2014CN04809A (fr)
HK1201196A1 (en) Treatment of ocular disease
IN2014CN03123A (fr)
MX2014000781A (es) Dosis combinada fija de bimatoprost y brimonidina.
HK1186660A1 (en) A water-in-oil type emulsion for treating a disease of the eye
EP3013425A4 (fr) Traitement et diagnostic d'une maladie oculaire
IN2015DN02501A (fr)
UY34843A (es) Tratamiento de enfermedades inflamatorias oculares usando laquinimod
EP3145532A4 (fr) Traitement individualisé d'une maladie de l' oeil
EP3182952A4 (fr) Modification de l'humidité sur un tissu glabre pour le traitement de la migraine et d'autres états
HK1220144A1 (zh) -叔丁基-苄基 -氯- -氯- -乙基-苯基 -乙基 -氟- -三氟甲基-苯甲酰胺用於治療眼疾病的用途
PH12015501211A1 (en) Use of pidotimod to treat atopic dermatitis
MX2016005505A (es) Modulador de la proteina de transferencia de ester de colesterilo (cetp) para usarse en el tratamiento de enfermedades oculares.
HK1216233A1 (zh) 含有四氫吡喃基氨基環戊基羰基四氫吡啶並吡啶衍生物作為有效成分的眼後段疾病的預防或治療劑
UA113065C2 (xx) Композиція для нанесення на шкіру та її застосування
UA111645C2 (uk) Ефективна доставка ліпідів у слізну плівку людини з використанням чутливої до солі емульсійної системи
PL401911A1 (pl) Zastosowanie preparatu o wlasciwosciach immunoregulatorowych
CN302327175S (zh) 眼镜
MX2013006527A (es) Derivados de arilsulfonamida para la prevencion o el tratamiento de los trastornos oftalmologicos especificos.